更新
3月7日 - **Neumora Therapeutics NMRA.O股价盘前下跌11.2%至1.35美元，将打破三日连涨的势头。
** 强生
** 作为 NMRA 2023 年 首次公开募股的六家联合账簿管理人之一，券商 Stifel将其 评级从 "买入 "下调 至 "持有"。
** Stifel 表示："我们一直认为 Aticaprant 的成功......是验证 KORA 机制的重要依据。
** 1 月初，实验性药物 navacaprant 在抑郁症患者中的后期试验 (link) 失败后，NMRA 股价暴跌约 80
** 自 2023 年 9 月 IPO 以来股价下跌约 90
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.